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Vitamin Supplementation Reduces
Blood Homocysteine Levels
A Controlled Trial in Patients With Venous Thrombosis
and Healthy Volunteers
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Pierre W Wyermans, Wim BJ Gemts
Abstract—Hyperhomocystememia is a nsk factor for atherosclerosis and thrombosis and is mversely related to plasma folate
and Vitamin B12 levels We assessed the effects of Vitamin Supplementation on plasma homocysteme levels m 89 patients
with a history of recurrent venous thrombosis and 227 healthy volunteers Patients and hyperhomocysteinemic
(homocysteme level >16 ;u.mol/L) volunteers were randomized to placebo or high-dose multiVitamin Supplements
contaming 5 mg folic acid, 0 4 mg hydroxycobalamm, and 50 mg pyndoxme A subgroup of volunteers without
hyperhomocystememia was also randomized into three additional regimens of 5 mg folic acid, 0 5 mg folic acid, or 0 4
mg hydroxycobalamm Before and after the Intervention penod, blood samples were taken for measurements of
homocysteme, folate, cobalamm, and pyndoxal-5'-phosphate levels Supplementation with high-dose multivitamm
preparations normalized plasma homocysteme levels (^16 μπιοΙ/L) m 26 of 30 mdividuals compared with 7 of 30 in the
placebo group Also m normohomocystememic subjects, multivitamin Supplementation strongly reduced homocysteme
levels (median reduction, 30%, ränge, —22% to 55%) In this subgroup the efFect of folic acid alone was sirmlar to that of
multivitamin median reduction, 26%, ränge, —2% to 52% for 5 mg folic acid and 25%, ränge, —54% to 40% for 0 5 mg
folic acid Cobalamm Supplementation had only a shght efFect on homocysteme lowenng (median reduction, 10%, ränge,
—21% to 41%) Our study shows that combmed Vitamin Supplementation reduces homocysteme levels effectively in
patients with venous thrombosis and m healthy volunteers, either with or without hyperhomocystememia Even
Supplementation with 0 5 mg of folic acid led to a substantial reduction of blood homocysteme levels (Artertoscler Thromb
Vase Biol. 1998;18:356-361.)
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Subjects with hyperhomocystememia have a twofold to three-fold increase in nsk of developmg cardiovascular disease or
venous thrombosis' 5 Reduction of plasma homocysteme levels
by Vitamins may therefore be of major climcal importance Several
studies have investigated the homocysteme-lowenng properties of
pyndoxine (vitamin B6), hydroxycobalamm (vitamin B12), or
folic acid alone or in combinataon6 " However, some of diese
studies were not placebo controlled, and therefore, they cannot
distmguish the extent to which the observed eiFects were due to
regression to the mean Other studies were restncted to hyper-
homocystememic subjects, healthy volunteers, or certam sub-
groups (eg, elderly people, men, women, or patients with
cardiovascular disease or renal fadure)
The aim of our study was to estimate and compare the homocys-
teine-lowenng effect of vitamin Supplementation in patients with
hyperhomocysteinerma-related disease and in healthy volunteers with
or without elevated homocysteme levels Therefore, we studied the
eflects of an 8-week dady combmed admirustration of 5 mg folic acid
0 4 mg hydroxycobalamm, and 50 mg pyndoxine versus placebo on
blood homocysteme levels in patients with a history of recurrent
venous thrombosis and healthy volunteers We also compared this
high-dose multivitamin regimen with single-vitarmn regimens of
folate or hydroxycobalamm to assess which vitamin at which dose
was the most effecüve in lowenng homocysteme levels For reasons
of sample size, we restncted this "drug- and dose-finding study" to
volunteers with normohomocysteinemia Finally, we analyzed the
influence of initial homocysteme and vitamin concentrations and of
the 677C—»T mutaoon in the methylenetetrahydrofokte reductase
(MTHFR) gene on the homocysteme-lowenng efiect of multivita-
min supplementaflon
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Methods
The study group was recruited from subjects vvho had participated m
a previous case-control study4 In the current study, 92 ot the 185
patients with recurrent venous thrombosis and 230 of the 500
volunteers from the general population agreed to participate m an
8-week daily Vitamin supplementation tnal Six participants (three
from each group) withdrew dunng the study All participants were
asked not to take ("self-prescnbed") vitarmn Supplements for at least 2
months pnor to the Start of the current study
Both patients and hyperhomocystemermc healthy volunteers were
randomtzed to either a placebo or a high-dose multiVitamin schedule
Each multivitamin tablet contamed 5 mg folic acid, 0 4 mg hydroxy-
cobalarrun, and 50 mg pyndoxine (Randomization of the volunteers
had been stratified by homocysteme level m a previous study4 [cutoff
pomt, 16 μηιοΙ/L] ) Volunteers with previous homocysteme levels
£16 μηιοΙ/L were randomized to placebo, multivitamin, or smgle-
vitamin regimens (5 mg folic acid, 0 5 mg fohc acid, or 0 4 mg
hydroxycobalamm) These three additional subregimens were re-
stncted to normocystememic volunteer group because the other
subgroups were too small to allow randomization mto more than two
schedules Randomization was performed by usmg the last digit of
each patient's number So all hyperhomocystememic subjects and
normocystememic patients with recurrent venous thrombosis with an
odd or even number were assigned to the multivitamin or placebo
group, respectively In the normohomocystememic healthy volun-
teers, subjects with a last digit of 0 or l were assigned to placebo, 2 and
3, to multiVitamins, 4 and 5, to 5 mg folic acid,, 6 and 7, to 0 5 mg
fohc acid, and 8 and 9, to 0 4 mg Vitamin B12 All subjects were asked
to take l tablet per day for 56 days The tnal was kept double-bhnd
Before and after the supplementation penod, blood was collected after
an overrught fast for homocysteme, folate, cobalamm, and pyndoxal-
5'-phosphate measurements
For homocysteme and Vitamin measurements, blood samples were
taken from the antecubital vem and collected mto EDTA-contaimng
tubes Whole blood was stored at —70°C for pyndoxal-5'-phosphate
determination For the other determmations, EDTA-treated samples
were immediately placed on ice and centnfuged within half an hour at
2000g for 10 minutes The plasma was separated and stored at — 20°C
The EDTA-treated samples for folate and cobalamm measurements
were stored at — 70°C and analyzed within 2 months Folate and
cobalamm concentration:, were measured with a Dualcount SPNB
(sohd phase no boil) radioassay kit (Diagnostic Products Corp)
Determination of pyndoxal-5'-phosphate was performed by high-
performance liquid chromatography techniques accordmg to Schnjver
et al12 with some modifications 13 Total homocysteme concentrations
were measured accordmg to the method descnbed by Fiskerstrand et
al14 with some modifications '5 Mutation analysis was carned out by
means of polymerase-cham reaction and restnction enzyme digestion
äs descnbed elsewhere 1δ
In the analysis we first looked at normalization rates of homocys-
teme levels after multivitamin or placebo supplementation Therefore,
we calculated the fraction of hyperhomocystememic subjects (homo-
cysteme >16 μιηοΙ/L in the present study) who became normoho-
mocystememic (homocysteme £16 μπιοΙ/L) after the supplementa-
tion penod The cutofF pomt was a rounded value based on the 80th
percentile m our previous study 4 Second, we calculated the percent
homocysteme reduction for each subject and compared the median
reduction in the different Vitamin supplementation groups with
respect to the correspondmg placebo group To compare the homo-
cysteme-lowenng effects m paaents and volunteers, we later stratified
the patients mto a hyperhomocystememic and a normohomocysteme-
mic group accordmg to their homocysteme levels äs determmed in our
previous study (cutoffpomt, 16 μηιοΙ/L) Fmally, we studied deter-
mmants of the homocysteme-lowenng effect of multivitamin supple-
mentation by calculatmg the median reduction in men and women, in
subjects under or above 53 years of age (median age of healthy
volunteers), and for several strata (tertiles) of initial homocysteme,
folate, cobalamm, and pyndoxal-5'-phosphate concentrations, äs well
äs for the three different MTHFR-genotypes (677C—>T) To evaluate
the difference m median reduction, we used the Mann-Whitney U
test for unpaired cases (SPSS Software) All participants gave their
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A
0 10 20 30
tHcy (μπιοΙ/L) before Intervention





|4» l) > ·
/ ·
«Λ\. . <69C|> '
0
tHcy (pmol/L) before Intervention
tHcy (pmol/L) after Intervention
D
0 10 20 30 40
tHcy (pmol/L) before Intervention
0 10 20 30 40
tHcy (μηιοΙ/L) before Intervention
Total plasma homocysteme (tHcy) levels before (x axis) and after
<y axis) 8 weeks of daily multivitamin or placebo supplementa-
tion m patients with a history of recurrent venous thrombosis (A,
placebo group, B, multivitamin group) and in healthy volunteers
(C, placebo group, D, multivitamin group) The multivitamin tab-
lets contamed 5 mg folic acid, 0.4 mg hydroxycobalamm, and
50 mg pyndoxine
mformed, wntten consent, and the study protocol was approved by
the medical ethics committee of Leyenburg Hospital
Results
The median age of the patient group was 62 years (ränge, 31 to
89) and of the volunteers, 53 years (ränge, 23 to 82) The
median homocysteme concentration of the patient group was
13 6 μπιοΙ/L (ränge, 7 2 to 69) and of the volunteer group
128 μηιοΐ/ΐ, (ränge, 4 7 to 49 8)
The Figure shows the homocysteme concentrations before
and after Intervention for the placebo and mgh-dose multivi-
tamin groups of both patients and volunteers In the multivi-
tamin group, 11 of 14 hyperhomocystememic patients with
thrombosis had a normalized value after Intervention (cutoff
pomt, 16 μηιοΙ/L) compared with only 4 out 10 in the placebo
group A very similar observaüon was made m the healthy
volunteers
In the multivitamin group, 15 of 16 hyperhomocystememic
subjects had a normalized value (cutoff pomt, 16 μιτιοΙ/L)
compared with only 3 of 20 m the placebo group So for all
hyperhomocystememic mdividuals together, 26 of 30 subjects
had normalized homocysteme levels (<16 μιηοΙ/L) after
supplementation with multiVitamins compared w'th only 7 of
30 m the placebo group
Table l shows that there was no clear diffe ence between
patients with recurrent venous thrombosis and Healthy volun-
teers with respect to their homocysteme-lowenng response
due to multivitamin supplementation In both groups there
was also a substantial effect in the normohomoc/stememic
subjects
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TABLE 1. Homocysteine-Lowering Effect of Multivitamin or Placebo Supplementation in Patients With
Recurrent Venous Thrombosis and in Healthy Volunteers
Study Subjects































































tHcy indicates total plasma homocysteme The homocysteme Iowermg effect
homocysteme concentration alter Intervention
'Stratified on homocysteme levels m the previous study
tContammg 5 mg folic acid 04 mg hydroxycobalamm and 50 mg pyndoxme
ΦΡ< 001 compared with the correspondmg placebo group
is expressed äs the median percent reduction m
In Table 2 we compared the homocysteme-lowenng effect
of several smgle-vitamm regimens in volunteers who were
normohomocysteinermc in a previous study From these data
we may conclude that the effect of 5 mg folic acid, even a low
dose of 0 5 mg, is nearly äs effective äs the multivitamm
regimen In contrast, Vitamin B12 only slightly decreased the
homocysteme concentration
In Table 3 we analyzed the effects of age and sex with
respect to the homocysteme-lowenng effect of multivita-
min Supplementation For reasons of homogeneitv, we
restncted this analysis to volunteers who had been random-
ized mto either the placebo or the multivitamm group
(n= 120) We found a similar homocysteme-lowenng efFect
in men and women and m subjects under and above 53 years
of age
In Table 4 we stratified the homocysteme-lowenng effect
on tertiles of initial homocysteme, folate, cobalarrun, and
pyndoxal-5'-phosphate levels We found a stronger homocys-
teme-lowenng effect in subjects with high initial homocys-
teme levels However, even m subjects with an initial homo-
cysteme level of <11 8 μ,ηιοΙ/L, we still found a median
reduction of 21% (ränge, —22 to 41%) An mverse effect was
seen with respect to initial vitamm concentrations The ho-
mocysteme-lowenng effect was strengest in subjects with low
folate, cobalarrun, or pyndoxal-5'-phosphate concentrations
Six of the 92 patients with recurrent venous thrombosis
were homozygous for the 677C—»T mutation versus 22 of the
230 control subjects (odds ratio, 0 7, 95% confidence interval,
0 3 to l 7) In Table 4 we also show that the homocysteme-
lowenng effect of multivitamm Supplementation was not
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tHcy indicates total plasma homocysteme The homocysteme-lowenng effect is expressed äs the median percent reduction m homocysteme
concentration alter Intervention
'Containing 5 mg folic acid 0 4 mg hydroxycobalamm and 50 mg pyndoxme
tP< 001 compared with the placebo group
tP=14
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TABLE 3. Homocysteme-Lowering Effect of Multivitamin or Placebo Supplementation in























































tHcy mdicates total plasma homocysteme The homocysteme lowermg effect is expressed äs the median percent reduction
m homocysteme concentration after Intervention
*Contammg 5 mg folic acid 0 4 mg hydroxycobalamm and 50 mg pyndoxme
impaired in subjects homozygous for the 677C—»T mutation
and m fact, rrught even be stronger
Discussion
We investigated the effect of multivitarmn supplementation on
homocysteme levels m patients with recurrent venous throm-
bosis and healthy volunteers firom the general population We
found that combmed supplementation with folic acid, hy-
droxycobalamm, and pyndoxme effectively reduced and nor-
mahzed homocysteme levels in patients with recurrent venous
thrombosis äs well äs in healthy volunteers For a subgroup of
normohomocystememic volunteers, folic acid at a dose of 5
mg or even 0 5 mg seemed to be almost äs effective äs the
high-dose multivitamm supplementation Oral cobalamm sup-
plementation had only a moderate effect on homocysteme
levels
In 1985 Brattstrom et al6 reported a substantial homocys-
teme reduction m 15 volunteers who received 5 mg folic acid
per day for 4 weeks Wilcken et al7 reported a homocysteme-
lowermg effect of folic acid supplementation m patients with
chromc renal msufHciency Franken et al8 and van den Berg et
al9 reported sigruficant reductions in postmethionme-loading
homocysteme concentrations with Vitamin B6 folic acid, or a
combmaüon of both m patients with vascular disease Al-
though these studies were performed in large groups of
patients, they were not placebo controlled and were restncted
to hyperhomocystememic subjects, which charactenstics make
them rather sensitive to regression to the mean Ubbink et al10
studied the effects of l mg folic acid, 0 4 mg cyanocobalamm,
and 122 mg pyndoxal HC1 alone or m combination m a
placebo-controlled study in subjects with hyperhomocysteme-
mia High-dose multivitamm admmistration resulted in a
49 8% reduction of the mean homocvsteme level Naurath et
al" studied the effect of mtramuscular Vitamin supplementation
with folate, vitamm B6, and Vitamin B12 m elderly subjects
with blood vitamm concentrations in the normal ränge
In our study we were able to compare the effects in patients
with homocysteme-related disease (venous thrombosis) with
those in healthy volunteers These effects were quite sirmlar
We also found about the same effects in men compared with
women and m subjects under and above 53 years of age The
strongest homocysteme-lowering effect of vitamm supplemen-
tation was seen m subjects with high initial homocysteme
and/or low initial vitamm concentrations However, we also
observed a moderate reduction m homocysteme levels m
subjects with homocysteme and vitamm levels within the
normal ränge This observation raises the question of "normal"
homocysteme and vitamm levels Our defimtion of hyperho-
mocystmemia at the 80th percentile of the distnbution in the
general population is arbitrary Other suggested defimtions are
based on mean concentrations m populations without cardio-
vascular disease " at the flat plateau of the homocysteme-folate
plot18 We thmk that the best defimtion should be based on
clmical Intervention studies the lowest concentration at which
vitamm supplementation reduces the nsk of vascular disease
However, data on clmical studies are not yet available
In a subgroup of normohomocystememic volunteers, we
found approximately the same homocysteme-lowenng effect
of folic acid at a dose of 0 5 mg äs with a dose of 5 mg This
means that considerably low doses of folic acid supplementa-
tion are effective m lowenng homocysteme levels Further
studies are needed to see whether doses lower than 0 5 mg may
also be effective
Although folic acid supplementation seems to be the cor-
nerstone in the treatment of hyperhomocystememia, there are
some reasons for addmg cobalamm and pyndoxme First, this
combination may have a stronger effect m subjects with low
cobalamm or pyndoxme levels Second, folate admmistration
alone might mask vitamm B12 deficiency Addition of cobal-
amm in sufficient dose prevents the complications of vitamm
B12 deficiency, such äs subacute combmed degeneration of the
spinal cord, even m the case of permcious anemia " We did
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TABLE 4. Homocysteine-Lowering Effect of Multivitamin ur Placebo Supplementation
Stratified Over Tertiles of Homocysteine, Folate, Cobalamin, and Pyridoxal-5'-Phosphate








































































































































9 3 (7 8-21 4)



































tHcy mdicates tal plasma homocysteme, MTHFR, methylenetetrahydrofolate reductase The homocysteme-lowenng effect
is expressed äs the percent reduction m homocysteme concentration after Intervention
*Contaming 5 mg folic acid, 0 4 mg hydroxycobalamm, and 50 mg pyndoxme
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not study doses higher than 50 mg pyndoxme because higher
doses may cause sensory neuropathy 2U 2I
Recently, we found the 677C—>T mutation in the
MTHFR gene162223 This mutation is associated with elevated
homocysteme levels, but it is unclear whether this mutation is
also associated with artenal vascular disease 24 In this study the
prevalence of the 677C—>T mutation m the recurrent venous
thrombosis group did not really difFer from that m the control
group This finding is in accordance with the results in a study
of first-time venous thrombosis 2D We found that the homo-
cysteme-lowenng efFect in subjects with this mutation en
might be even stronger than in those without this mutation
This finding is in accordance with the study of Malmow et al,26
These results suggest that the efFect of a mutated MTHFR
might be "compensated" by a higher folate mtake
In conclusion, our study shows that combmed supplemen-
tation with fohc acid, cobalamin, and pyndoxme reduces
homocysteme levels by =«30% compared with placebo within
8 weeks in patients with recurrent venous thrombosis äs well äs
m healthy volunteers. Whether the reduction in homocysteme
levels by vitamm supplementation will lead prevention of
artenal vascular disease and venous thrombosis is a major task
for further climcal research.27 28
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